ISSN: 1092-8529

Journal Guideline

CNS Spectrums Q2 Unclaimed

Cambridge University Press United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

CNS Spectrums is a journal indexed in SJR in Neurology (clinical) and Psychiatry and Mental Health with an H index of 77. It has a price of 1626,56 €. It has an SJR impact factor of 0,99 and it has a best quartile of Q2. It is published in English.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Neurology (clinical) (Q2) Psychiatry and Mental Health (Q2)

Price

1626,56 €

Gold OA

-

Green OA

- €

Non OA

Metrics

0,99

SJR Impact factor

77

H Index

215

Total Docs (Last Year)

180

Total Docs (3 years)

6916

Total Refs

461

Total Cites (3 years)

157

Citable Docs (3 years)

2,7

Cites/Doc (2 years)

32,17

Ref/Doc

Aims and Scope

Other journals with similar parameters

Neurology and Therapy Q2
Brain Research Q2
Journal of Huntington's disease Q2
Multiple Sclerosis and Demyelinating Disorders Q2
Cerebellum and Ataxias Q2

Best articles

A brief history of the criminalization of mental illness

A Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible-Dose Desvenlafaxine Treatment in Outpatients with Major Depressive Disorder

Acute Stress Reactions: Can Biological Responses Predict Posttraumatic Stress Disorder?

Altered brain functional networks in Internet gaming disorder: independent component and graph theoretical analysis under a probability discounting task

Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish

Antineuroinflammatory therapy: potential treatment for autism spectrum disorder by inhibiting glial activation and restoring synaptic function

Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD)

Behavioral addictions: a novel challenge for psychopharmacology

Beyond Monoamines: Glutamatergic Function in Mood Disorders

Bringing New Order to Neuroscience

Cognitive dysfunction in body dysmorphic disorder: new implications for nosological systems and neurobiological models

Cognitive impairment in substance use disorders

SHOW MORE ARTICLES

Cognitive-Affective Neuroscience of Depersonalization

Commentary

Comorbid mental illness and criminalness implications for housing and treatment

Complexity in Science: Syntaxis Versus Semantics

Compulsive and Addictive Sexual Disorders and the Family

Computer Applications in Psychiatry

Daily life impairments associated with childhood/adolescent attention-deficit/hyperactivity disorder as recalled by adults: results from the European Lifetime Impairment Survey

Decriminalizing LGBTQ+: Reproducing and resisting mental health inequities

Detection and treatment rates for perinatal depression in a state Medicaid population

Do cognitive and neuropsychological functioning deficits coincide with hippocampal alteration during first-psychotic episode?

Does Obsessive-Compulsive Personality Disorder Belong Within the Obsessive-Compulsive Spectrum?

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy

Comments

No comments ... Be the first to comment!

Publication speed

Review quality

Edition and editorial team

Paper Link

Attach one of your papers. We need to confirm that you have had a relation with this journal in order to review its service.